Gordon Research Conferences
PI_Conferences PI_Conferences_Current
Conference Program
 
Angiotensin
The Renin-Angiotensin System Beyond Angiotensin II
March 2-7, 2014
Renaissance Tuscany Il Ciocco Resort
Lucca (Barga), Italy

Related Meeting Information
The Angiotensin Gordon Research Conference was held in conjunction with the Angiotensin Gordon Research Seminar. Please refer to the Angiotensin GRS web page for more information.

The RAS plays a vital role in virtually every cardiovascular disease, and drugs blocking this system are widely used. Three classes can be distinguished, which in essence all block the same renin-ACE-angiotensin II-AT1 receptor pathway. Although for many years it was argued 'the more blockade, the better’, recent trials have shown that this is not the case. In fact, at perhaps slightly more benefit, there are also more side effects. Clearly therefore, we have reached the maximum benefit that can be obtained from blocking this pathway, and we should focus on new RAS components/pathways to interfere with. Indeed, in the last few years multiple new possibilities have emerged: the (pro)renin receptor (which activates renin’s inactive precursor, prorenin), the AT2 receptor (which appears to be stimulated by angiotensin III) and the ACE2-angiotensin-(1-7)-Mas receptor pathway. In addition, angiotensin II stimulates the synthesis and release of aldosterone. Aldosterone receptor antagonists are important tools in resistant hypertension. Simultaneously, new aldosterone receptors emerge, and aldosterone synthase inhibitors are being tested as potential treatment modalities. AT2 receptor (ant)agonists are currently being evaluated clinically, and this is also true for drugs interfering with the ACE2-angiotensin-(1-7)-Mas receptor pathway. Summarizing, the RAS field is rapidly moving "beyond" angiotensin II, and many new drugs start to emerge, including drugs that act on one specific signaling pathway of angiotensin II ("biased AT1 receptor agonists"). The Angiotensin GRC is the only meeting where these topics come together in one meeting. It is THE discussion place for the latest RAS discoveries by investigators from all over the world - all attendants are stimulated to submit an abstract for poster presentation. Combined with a GRS it also attracts a lot of young scientists. Afternoons are saved for informal get-togethers. Discussions usually continue late into the night through convivial gatherings after the evening sessions.


Contributors

SUNDAY
4:00 pm - 8:00 pmArrival and Check-in (Check-in Desk Closed 6:00 pm - 7:45 pm)
6:00 pmDinner
7:30 pm - 7:35 pmWelcome / Introductory Comments by GRC Site Staff
7:35 pm - 7:40 pmWelcome / Introduction by GRC Chair Jan Danser (Erasmus University, Rotterdam, the Netherlands)
7:40 pm - 9:30 pmKeynote Session: Mouse Models and MR Activation
Discussion Leader: Jan Danser (Erasmus MC, Rotterdam, Netherlands)
7:40 pm - 8:25 pmTim Reudelhuber (Clinical Research Institute of Montréal, Montréal, Canada)
"The Promises and Pitfalls of Using the Mouse to Analyze the Renin-Angiotensin system"
8:25 pm - 8:35 pmDiscussion
8:35 pm - 9:20 pmToshiro Fujita (University of Tokyo, Tokyo, Japan)
"The Mechanism for Activation of Mineralocorticoid Receptor in the Heart and Kidney"
9:20 pm - 9:30 pmDiscussion
MONDAY
7:30 am - 8:30 amBreakfast
9:00 am - 10:50 amAT2 Receptors: Should We Stimulate or Block Them? / RAS and Cancer
9:00 am - 9:05 amDiscussion Leader: Muscha Steckelings (University of Southern Denmark, Odense, Denmark)
9:05 am - 9:25 amRob Widdop (Monash University, Melbourne, Australia)
"Novel AT2 Receptor Agonists for Cardiovascular Disease"
9:25 am - 9:35 amDiscussion
9:35 am - 9:55 amPraveen Anand (Imperial College, London, UK)
"AT2 Receptor Antagonism as Novel Treatment for Clinical Chronic Neuropathic Pain: Molecular Mechanisms and Signalling Pathways"
9:55 am - 10:05 amDiscussion
10:05 am - 10:25 amClara Nahmias (Université Paris-Descartes, Paris, France)
"AT2 Receptor-Interacting Protein ATIP3: A New Therapeutic Target for Breast Cancer"
10:25 am - 10:35 amDiscussion
10:35 am - 10:55 amRakesh Jain (Harvard Medical School and Massachusetts General Hospital, Boston, USA)
"Emerging Role of RAS Blockade in Cancer Treatment"
10:55 am - 11:05 amDiscussion
11:05 am - 11:30 amCoffee Break
11:30 am - 12:30 pmYoung Investigator Presentations
Discussion Leader: Kathryn Sandberg (Georgetown University, Washington DC, USA)
11:30 am - 11:40 amTakuo Hirose (Collège de France, Paris, France)
"The (Pro)renin Receptor and Brain Development"
11:40 am - 11:45 amDiscussion
11:45 am - 11:55 amTaiji Matsusaka (Tokai University School of Medicine, Kanagawa, Japan)
"Podocyte Injury Enhances Filtration of Liver-Derived Angiotensinogen and Renal Angiotensin II Generation"
11:55 am - 12:00 pmDiscussion
12:00 pm - 12:10 pmJiandong Zhang (Duke University, Durham, USA)
"Interleukin-1 Potentiates Sodium Retention in Angiotensin II-Dependent Hypertension Through NO-Dependent Regulation of Na+-K+-2Cl- Cotransporter"
12:10 pm - 12:15 pmDiscussion
12:15 pm - 12:25 pmNadja Grobe (Wright State University, Dayton, USA)
"Mass Spectrometry MALDI Imaging of the Renin-Angiotensin System Facilitates the Discovery of New Biomarkers for Chronic Kidney Disease"
12:25 pm - 12:30 pmDiscussion
12:30 pmLunch
1:30 pm - 4:30 pmFree Time
4:30 pm - 6:00 pmPoster Session
6:00 pm - 8:00 pmNew Drugs Arising from the ACE2-Ang(1-7)-Mas Receptor Axis
6:00 pm - 6:05 pmDiscussion Leader: Michael Bader (MDC, Berlin, Germany)
6:05 pm - 6:25 pmRodrigo Fraga-Silva (Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland)
"Preclinical and Clinical Data of the Angiotensin-(1-7)/Hydroxypropyl-β-Cyclodextrin Inclusion Compound"
6:25 pm - 6:35 pmDiscussion
6:35 pm - 6:45 pmMohan Raizada (University of Florida, Gainesville, USA)
"Oral Delivery of ACE2/Ang-(1-7) Bioencapsulated in Plant Cells Attenuates Pulmonary Hypertension and Associated Cardiac Dysfunctions"
6:45 pm - 6:50 pmDiscussion
6:50 pm - 7:10 pmStuart Nicklin (Universiy of Glasgow, Glasgow, UK)
"Assessing Ang-(1-7) and Ang-(1-9) in Cardiac and Vascular Remodelling"
7:10 pm - 7:20 pmDiscussion
7:20 pm - 7:25 pmMaria Grant (Indiana University, Indianapolis, USA)
"Preservation of Ang-(1-7)/Mas Pathway Activation in CD34+ cells is Associated with Reduced Severity of Diabetic Retinopathy"
7:25 pm - 7:30 pmDiscussion
7:30 pm - 7:50 pmKathleen Rodgers (University of Southern California, Los Angeles, USA)
"Development of Angiotensin-(1-7) as a Therapeutic for Regenerative Medicine"
7:50 pm - 8:00 pmDiscussion
8:00 pmDinner
TUESDAY
7:30 am - 8:30 amBreakfast
8:30 amGroup Photo
9:00 am - 12:30 pmAortic Pathologies: From Mouse to Man / RAS, Gender & Preeclampsia
9:00 am - 9:05 amDiscussion Leader: Lisa Cassis (University of Kentucky, Lexington, USA)
9:05 am - 9:35 amAlan Daugherty (University of Kentucky, Lexington, USA)
"Mechanistic Insight into the Role of the Renin-Angiotensin System in Aortic Aneurysms"
9:35 am - 9:45 amDiscussion
9:45 pm - 9:50 amTakashi Obama (Temple University School of Medicine, Philadelphia, USA)
"Vascular Smooth Muscle ADAM17 Contributes to Angiotensin II-Induced Abdominal Aortic Aneurysm Formation but not Hypertension in Mice"
9:50 pm - 9:55 amDiscussion
9:55 am - 10:25 amBart Loeys (University of Antwerp, Antwerp, Belgium)
"Marfan Syndrome and Related Disorders: From Gene to Therapy"
10:25 am - 10:35 amDiscussion
10:35 am - 11:05 amCoffee Break
11:05 am - 11:10 amDiscussion Leader: Kate Denton (Monash University, Melbourne, Australia)
11:10 am - 11:35 amAnne Staff (Oslo University Hospital, Oslo, Norway)
"Preeclampsia, Placenta and Future Cardiovascular Disease: Is There a Connection and Does the RAS Play a Role"
11:35 am - 11:45 amDiscussion
11:45 am - 11:50 amKirsty Pringle (University of Newcastle, Callaghan, Australia)
"The Intrarenal Renin-Angiotensin System in Pregnancy and Its Potential in Predicting Renal Dysfunction and Fetal Kidney Development in Indigenous and Non-Indigenous Australian Women"
11:50 am - 11:55 amDiscussion
11:55 am - 12:20 pmJames Pearson (Monash University, Melbourne, Australia)
"Exploring RAS Roles in Sex Differences in Coronary Dysfunction in Insulin Resistance Using Synchrotron Imaging"
12:20 pm - 12:30 pmDiscussion
12:30 pmLunch
1:30 pm - 4:30 pmFree Time
4:30 pm - 6:00 pmPoster Session
6:00 pm - 8:00 pmRAS and Ageing
6:00 pm - 6:05 pmDiscussion Leader: Anton Roks (Erasmus MC, Rotterdam, The Netherlands)
6:05 pm - 6:40 pmMartin Bennett (Addenbrooke's Centre for Clinical Investigation, Cambridge, UK)
"Control and Consequences of Vascular Ageing"
6:40 pm - 6:50 pmDiscussion
6:50 pm - 7:20 pmIris Jaffe (Tufts University School of Medicine, Boston, USA)
"Smooth Muscle Cell Mineralocorticoid Receptors: Global Regulators of Cardiovascular Aging"
7:20 pm - 7:30 pmDiscussion
7:30 pm - 7:40 pmHiroshi Akazawa (University of Tokyo, Tokyo, Japan)
"Angiotensin II Receptor Blockade Reduces Aging-Promoting C1q Expression and Promotes Repair of Skeletal Muscle"
7:40 pm - 7:45 pmDiscussion
7:45 pm - 7:55 pmHaiyan Wu (Erasmus MC, Rotterdam, The Netherlands)
"The Effect of Genomic Instability on Vascular Angiotensin II Responses: Implications for Aging of the Renin-Angiotensin System"
7:55 pm - 8:00 pmDiscussion
8:00 pmDinner
WEDNESDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmRAS (Blockade) Readouts: Focus on Urine / RAS and Clinical Conundrums
9:00 am - 9:05 amDiscussion Leader: Akira Nishiyama (University of Kagawa, Kagawa, Japan)
9:05 am - 9:30 amJanos Peti-Peterdi (University of California, Los Angeles, USA)
"Intravital Imaging of the Glomerular Filtration and Tubular Handling of RAS Elements"
9:30 am - 9:40 amDiscussion
9:40 am - 10:05 amChristian Delles (University of Glasgow, Glasgow, UK)
"The RAS in the Era of Stratified/Precision Medicine"
10:05 am - 10:15 amDiscussion
10:15 am - 10:40 amEwout Hoorn (Erasmus MC, Rotterdam, The Netherlands)
"Urinary Exosomes: Biomarkers for the Effect of the Renin-Angiotensin System on the Kidney"
10:40 am - 10:50 amDiscussion
10:50 am - 11:15 amCoffee Break
11:15 am - 11:20 amDiscussion Leader: Massimo Volpe (University of Rome, Rome, Italy)
11:20 am - 11:45 amMichel Azizi (Hôpital Européen Georges Pompidou, Paris, France)
"MR Blockade or Aldosterone Synthase Inhibition for Hypertension?"
11:45 am - 11:55 amDiscussion
11:55 am - 12:20 pmHiddo Lambers Heerspink (University of Groningen, Groningen, The Netherlands)
"Individual Variability in Response to RAAS Inhibition - Can We Overcome It?"
12:20 pm - 12:30 pmDiscussion
12:30 pmLunch
1:30 pm - 4:30 pmFree Time
4:30 pm - 6:00 pmPoster Session
6:00 pm - 8:00 pmRAAS vs. RAS: What is So Important About Aldosterone?
6:00 pm - 6:05 pmDiscussion Leader: Gian Paolo Rossi (University of Padua, Padua, Italy)
6:05 pm - 6:30 pmUte Scholl (Yale University School of Medicine, New Haven, USA)
"Aldosterone-Producing Adenomas and Mendelian Hypertension - New Insights from Genetic Studies and Potential Clinical Applications"
6:30 pm - 6:40 pmDiscussion
6:40 pm - 7:05 pmAurelie Nguyen Dinh Cat (University of Glasgow, Glasgow, Scotland)
"Altered Vascular Reactivity in Mice Overexpressing Adipocyte Mineralocorticoid Receptors - Role of Rho Kinase and Oxidative Stress"
7:05 pm - 7:15 pmDiscussion
7:15 pm - 7:20 pmDevy Deliyanti (Monash University, Melbourne, Australia)
"Retinal Vasculopathy is Reduced by Dietary Salt Restriction: Involvement of Glia, ENaCa and the RAAS"
7:20 pm - 7:25 pmDiscussion
7:25 pm - 7:50 pmLivia Lenzini (University of Padua, Padua, Italy)
"The TWIK-Related Acid-Sensitive K+ Channels in Human Primary Aldosteronism"
7:50 pm - 8:00 pmDiscussion
8:00 pmDinner
THURSDAY
7:30 am - 8:30 amBreakfast
8:30 am - 9:00 amBusiness Meeting
Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair
9:00 am - 12:30 pmBiased AT1 Receptor Agonism / Novel Neural Control Mechanisms
9:00 am - 9:05 amDiscussion Leader: Tom Coffman (Duke University, Durham, USA)
9:05 am - 9:40 amHoward Rockman (Duke University, Durham, USA)
"Ligand Independent and Beta-Arrestin-Biased Signaling by AT1 Receptors in the Heart"
9:40 am - 9:50 amDiscussion
9:50 am - 9:55 amAndras Balla (Semmelweis University, Budapest, Hungary)
"Investigation of the Fate of Type I Angiotensin Receptor After Biased Activation"
9:55 am - 10:00 amDiscussion
10:00 am - 10:35 amConrad Cowan (Trevena Inc., King of Prussia, USA)
"Therapeutic Applications of AT1 Receptor Biased Agonists in Cardiovascular Disease"
10:35 am - 10:45 amDiscussion
10:45 am - 11:15 amCoffee Break
11:15 am - 11:20 amDiscussion Leader: Geneviève Nguyen (Collège de France, Paris, France)
11:20 am - 11:45 amMatthias Groszer (Inserm U839, Institut du Fer à Moulin, Paris, France)
"The (Pro)renin Receptor in CNS Development and Function"
11:45 am - 11:55 amDiscussion
11:55 am - 12:20 pmJustin Grobe (University of Iowa, Iowa City, USA)
"The Brain RAS: A Major Controller of Resting Metabolism"
12:20 pm - 12:30 pmDiscussion
12:30 pmLunch
1:30 pm - 4:30 pmFree Time
4:30 pm - 6:00 pmPoster Session
6:00 pm - 8:00 pmRAS Controversies: Where Do We Go From Here?
6:00 pm - 6:05 pmDiscussion Leader: Rhian Touyz (University of Glasgow, Glasgow, Scotland)
6:05 pm - 6:30 pmJock Campbell (St. Vincent Institute of Medical Research, Melbourne, Australia)
"Perspective on Angiotensin Peptides"
6:30 pm - 6:40 pmDiscussion
6:40 pm - 7:05 pmDavid Harrison (Vanderbilt University School of Medicine, Nashville, USA)
"The Immune System, Angiotensin II and Hypertension"
7:05 pm - 7:15 pmDiscussion
7:15 pm - 7:20 pmTom McCarthy (Spinifex Pharma, South Yarra, Australia)
"A Phase 2 Clinical Trial of EMA401, an Orally Administered Highly Selective Angiotensin II Type 2 Receptor Antagonist, in Patients with Post Herpetic Neuralgia"
7:20 pm - 7:25 pmDiscussion
7:25 pm - 7:50 pmRick Franklin (Tarix Pharmaceuticals, USA)
"Obstacles to Developing Angiotensin Peptide Drugs"
7:50 pm - 8:00 pmDiscussion
8:00 pmDinner
FRIDAY
7:30 am - 8:30 amBreakfast
9:00 amDeparture

Funding for this conference was made possible (in part) by 1R13HL121852-01A1 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Last Updated: February 26, 2014
 
© 2014 Gordon Research Conferences Search | Contact | Terms of Use | Privacy Policy | Follow us: Facebook Twitter